Total Payments
$7,114
2024 Payments
$273.92
Companies
32
Transactions
488
Medicare Patients
9,314
Medicare Billing
$717,988
Payment Breakdown by Category
Food & Beverage$6,944 (97.6%)
Education$170.42 (2.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,944 | 480 | 97.6% |
| Education | $170.42 | 8 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $1,182 | 87 | $0 (2023) |
| Amgen Inc. | $987.42 | 84 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $653.43 | 45 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $632.65 | 52 | $0 (2022) |
| Boston Scientific Corporation | $432.80 | 30 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $388.13 | 27 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $361.97 | 25 | $0 (2023) |
| Astellas Pharma US Inc | $348.51 | 15 | $0 (2021) |
| PFIZER INC. | $269.98 | 20 | $0 (2023) |
| Kiniksa Pharmaceuticals International, plc | $239.36 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $273.92 | 14 | Kiniksa Pharmaceuticals International, plc ($98.97) |
| 2023 | $849.48 | 37 | Novartis Pharmaceuticals Corporation ($173.17) |
| 2022 | $693.29 | 46 | Janssen Pharmaceuticals, Inc ($168.48) |
| 2021 | $869.41 | 63 | Janssen Pharmaceuticals, Inc ($232.38) |
| 2020 | $399.74 | 25 | Medtronic Vascular, Inc. ($102.35) |
| 2019 | $1,206 | 89 | Amgen Inc. ($179.89) |
| 2018 | $1,037 | 83 | Amgen Inc. ($254.39) |
| 2017 | $1,785 | 131 | Janssen Pharmaceuticals, Inc ($303.02) |
All Payment Transactions
488 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: DIABETES | ||||||
| 09/27/2024 | Medtronic, Inc. | TYRX (Device) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Antibacterial Mesh | ||||||
| 09/16/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/30/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Cardiology | ||||||
| 07/22/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $27.14 | General |
| Category: Not Applicable | ||||||
| 05/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: DIABETES | ||||||
| 05/13/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Not Applicable | ||||||
| 04/26/2024 | Medtronic, Inc. | AZURE XT DR MRI SURESCAN (Device) | Food and Beverage | In-kind items and services | $38.60 | General |
| Category: Pacemakers | ||||||
| 04/09/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: Not Applicable | ||||||
| 03/08/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: Not Applicable | ||||||
| 02/15/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: Not Applicable | ||||||
| 01/23/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Cardiology | ||||||
| 01/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/28/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $18.34 | General |
| Category: Not Applicable | ||||||
| 11/17/2023 | Medtronic, Inc. | AZURE XT DR MRI SURESCAN (Device) | Food and Beverage | In-kind items and services | $33.09 | General |
| Category: Pacemakers | ||||||
| 11/16/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/25/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/18/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $23.28 | General |
| Category: Not Applicable | ||||||
| 10/17/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/12/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/26/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $124.59 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/20/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $16.60 | General |
| Category: Not Applicable | ||||||
| 09/07/2023 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 2,672 | 3,302 | $619,850 | $192,837 |
| 2022 | 26 | 2,652 | 3,408 | $620,730 | $208,708 |
| 2021 | 25 | 2,523 | 3,269 | $533,500 | $206,032 |
| 2020 | 24 | 1,467 | 1,751 | $267,465 | $110,411 |
Total Patients
9,314
Total Services
11,730
Medicare Billing
$717,988
Procedure Codes
113
All Medicare Procedures & Services
113 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 632 | 658 | $131,600 | $33,557 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 183 | 229 | $45,800 | $20,064 | 43.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 148 | 152 | $53,200 | $19,731 | 37.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 227 | 279 | $33,480 | $16,451 | 49.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 52 | 102 | $60,600 | $15,800 | 26.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 106 | 207 | $55,850 | $14,586 | 26.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 121 | 121 | $36,300 | $14,097 | 38.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 129 | 224 | $24,640 | $13,347 | 54.2% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 51 | 102 | $22,440 | $8,817 | 39.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 113 | 114 | $34,200 | $6,463 | 18.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 29 | 34 | $11,220 | $5,305 | 47.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 341 | 404 | $26,260 | $3,969 | 15.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 44 | $5,940 | $3,962 | 66.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 19 | 76 | $6,840 | $3,177 | 46.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 54 | 54 | $15,120 | $2,452 | 16.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 23 | $3,450 | $2,231 | 64.7% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 116 | 117 | $9,360 | $1,835 | 19.6% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 116 | 117 | $23,400 | $1,214 | 5.2% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 11 | 12 | $3,000 | $973.80 | 32.5% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 18 | 46 | $2,990 | $954.19 | 31.9% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 11 | 11 | $5,500 | $886.27 | 16.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 19 | $1,140 | $712.31 | 62.5% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 18 | 46 | $2,530 | $693.16 | 27.4% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 21 | 21 | $840.00 | $352.17 | 41.9% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 16 | 16 | $1,200 | $301.28 | 25.1% |
About Dr. Mark Mataosky, M.D
Dr. Mark Mataosky, M.D is a Cardiovascular Disease healthcare provider based in Ladson, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699720821.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Mataosky, M.D has received a total of $7,114 in payments from pharmaceutical and medical device companies, with $273.92 received in 2024. These payments were reported across 488 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($6,944).
As a Medicare-enrolled provider, Mataosky has provided services to 9,314 Medicare beneficiaries, totaling 11,730 services with total Medicare billing of $717,988. Data is available for 4 years (2020–2023), covering 113 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Ladson, SC
- Active Since 05/24/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1699720821
Products in Payments
- XARELTO (Drug) $1,182
- ELIQUIS (Drug) $724.98
- Corlanor (Drug) $535.06
- ENTRESTO (Drug) $493.13
- Repatha (Biological) $452.36
- WATCHMAN (Device) $291.87
- PRADAXA (Drug) $290.78
- BRILINTA (Drug) $270.56
- Arcalyst (Drug) $239.36
- Reveal LINQ (Device) $201.17
- VERQUVO (Drug) $190.95
- LEXISCAN (Drug) $164.35
- LEQVIO (Drug) $160.30
- MULTAQ (Drug) $148.07
- Cardiac Monitoring Suite (Device) $139.91
- AZURE XT DR MRI SURESCAN (Device) $131.45
- CHANTIX (Drug) $129.78
- LifeVest (Device) $98.28
- WATCHMAN Access System (Device) $97.52
- Lexiscan (Drug) $94.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Ladson
Mr. Frederick Funke, Md, MD
Cardiovascular Disease — Payments: $19,511
Cardiovascular Disease $19,511
Dr. Jason Coker, M.d, M.D
Cardiovascular Disease — Payments: $17,792
Cardiovascular Disease $17,792
Christopher Mccarty, M.d, M.D
Cardiovascular Disease — Payments: $16,917
Cardiovascular Disease $16,917
Mark Coker, M.d, M.D
Cardiovascular Disease — Payments: $7,093
Cardiovascular Disease $7,093
Chris Kennedy, M.d, M.D
Cardiovascular Disease — Payments: $6,391
Cardiovascular Disease $6,391
Dr. Sofy Landes, Md, MD
Cardiovascular Disease — Payments: $5,151
Cardiovascular Disease $5,151